LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 70

Search options

  1. Article: Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis.

    Favalli, Ennio G

    Rheumatology and therapy

    2020  Volume 7, Issue 3, Page(s) 473–516

    Abstract: Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disorder involving inflammation and progressive destruction of the joints, affecting up to 1% of the population. The majority of patients with RA have one or more comorbid conditions, the ... ...

    Abstract Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disorder involving inflammation and progressive destruction of the joints, affecting up to 1% of the population. The majority of patients with RA have one or more comorbid conditions, the most common being cardiovascular disease, osteoporosis, and depression, the presence of which are associated with poorer clinical outcomes and lower health-related quality of life. RA pathogenesis is driven by a complex network of proinflammatory cells and cytokines, and of these, interleukin-6 (IL-6) plays a key role in the chronic inflammation associated with RA. Through cell signaling that can be initiated by both membrane-bound and soluble forms of its receptor, IL-6 acts both locally to promote joint inflammation and destruction, and in the circulation to mediate extra-articular manifestations of RA, including pain, fatigue, morning stiffness, anemia, and weight loss. This narrative review describes the role of IL-6 in the pathogenesis of RA, its comorbidities, and extra-articular systemic manifestations, and examines the effects of the IL-6 receptor inhibitors sarilumab and tocilizumab on clinical endpoints of RA, patient-reported outcomes, and common comorbidities and extra-articular manifestations.
    Language English
    Publishing date 2020-07-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2783278-8
    ISSN 2198-6584 ; 2198-6576
    ISSN (online) 2198-6584
    ISSN 2198-6576
    DOI 10.1007/s40744-020-00219-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Secukinumab in HLA-B27 associated uveitis.

    Miserocchi, Elisabetta / Giuffre, Chiara / Caporali, Roberto / Favalli, Ennio G

    Clinical & experimental ophthalmology

    2021  Volume 49, Issue 4, Page(s) 388–389

    MeSH term(s) Antibodies, Monoclonal, Humanized ; HLA-B27 Antigen ; Humans ; Uveitis/drug therapy
    Chemical Substances Antibodies, Monoclonal, Humanized ; HLA-B27 Antigen ; secukinumab (DLG4EML025)
    Language English
    Publishing date 2021-04-03
    Publishing country Australia
    Document type Letter
    ZDB-ID 2014008-3
    ISSN 1442-9071 ; 1442-6404
    ISSN (online) 1442-9071
    ISSN 1442-6404
    DOI 10.1111/ceo.13922
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Baricitinib for COVID-19: a suitable treatment?

    Favalli, Ennio G / Biggioggero, Martina / Maioli, Gabriella / Caporali, Roberto

    The Lancet. Infectious diseases

    2020  Volume 20, Issue 9, Page(s) 1012–1013

    MeSH term(s) Anti-Inflammatory Agents ; Antiviral Agents ; Azetidines ; Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2 ; Sulfonamides
    Chemical Substances Anti-Inflammatory Agents ; Antiviral Agents ; Azetidines ; Sulfonamides ; baricitinib (ISP4442I3Y)
    Keywords covid19
    Language English
    Publishing date 2020-04-03
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(20)30262-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Baricitinib for COVID-19

    Favalli, Ennio G / Biggioggero, Martina / Maioli, Gabriella / Caporali, Roberto

    The Lancet Infectious Diseases

    a suitable treatment?

    2020  Volume 20, Issue 9, Page(s) 1012–1013

    Keywords Infectious Diseases ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/s1473-3099(20)30262-0
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis.

    Maioli, Gabriella / Caporali, Roberto / Favalli, Ennio Giulio

    Expert opinion on drug discovery

    2022  Volume 17, Issue 8, Page(s) 799–813

    Abstract: Introduction: Rheumatoid arthritis (RA) pathogenesis is driven by a complex network of proinflammatory cytokines, among which interleukin-6 (IL-6) plays a key role in inducing and perpetuating chronic inflammation. Targeting the IL-6 pathway has shown ... ...

    Abstract Introduction: Rheumatoid arthritis (RA) pathogenesis is driven by a complex network of proinflammatory cytokines, among which interleukin-6 (IL-6) plays a key role in inducing and perpetuating chronic inflammation. Targeting the IL-6 pathway has shown to be an invaluable treatment strategy, as demonstrated by the results accrued in the last decade with the first IL-6 inhibitor, tocilizumab. More recently, a second monoclonal antibody blocking IL-6, sarilumab, has enriched our armamentarium by proving outstanding efficacy in RA treatment.
    Areas covered: After exploring the IL-6 pathway under physiological conditions and in the RA pathogenesis, in this review we discuss the pharmacologic properties of sarilumab and the clinical trials that constitute the sarilumab development program and have enabled its licensed application.
    Expert opinion: Results from clinical trials confirmed the efficacy and safety of sarilumab for the treatment of RA, similar to its precursor tocilizumab. Blocking IL-6 pathway results in comprehensive control of the disease, from both physician's and patient's perspective, and of RA comorbidities and extra-articular manifestations, which are largely IL-6 driven. Finally, the proven efficacy of sarilumab as monotherapy arises the drug as a required therapeutic alternative considering the large proportion of patients intolerant or inadequate to receive conventional synthetic disease-modifying drugs (csDMARDs).
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/drug therapy ; Humans ; Interleukin-6/therapeutic use ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antirheumatic Agents ; Interleukin-6 ; sarilumab (NU90V55F8I)
    Language English
    Publishing date 2022-06-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2259618-5
    ISSN 1746-045X ; 1746-0441
    ISSN (online) 1746-045X
    ISSN 1746-0441
    DOI 10.1080/17460441.2022.2093852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis.

    Cavalli, Giulio / Favalli, Ennio Giulio

    Expert review of clinical immunology

    2019  Volume 15, Issue 12, Page(s) 1313–1322

    Abstract: ... ...

    Abstract Introduction
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Arthritis, Rheumatoid/pathology ; Biological Products/therapeutic use ; Humans ; Observational Studies as Topic ; Randomized Controlled Trials as Topic ; Remission Induction
    Chemical Substances Antirheumatic Agents ; Biological Products
    Language English
    Publishing date 2019-11-10
    Publishing country England
    Document type Journal Article ; Review ; Video-Audio Media
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2020.1686976
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review.

    van der Horst-Bruinsma, Irene E / Robinson, Philip C / Favalli, Ennio G / Verbraak, Frank D / Kim, Mindy / Kumke, Thomas / Bauer, Lars / Hoepken, Bengt / Deodhar, Atul

    Rheumatology and therapy

    2022  Volume 9, Issue 6, Page(s) 1481–1497

    Abstract: Background: Acute anterior uveitis (AAU) affects up to 40% of patients with axial spondyloarthritis (axSpA). An effective treatment for patients with axSpA that reduces the risk of AAU flares while also targeting axial symptoms is therefore highly ... ...

    Abstract Background: Acute anterior uveitis (AAU) affects up to 40% of patients with axial spondyloarthritis (axSpA). An effective treatment for patients with axSpA that reduces the risk of AAU flares while also targeting axial symptoms is therefore highly desirable. Tumor necrosis factor inhibitors (TNFis) have been shown effective for treatment of axSpA and AAU occurrence, with guidelines conditionally recommending treating patients with axSpA and associated AAU with TNFi monoclonal antibodies. To date, most available data on the impact of TNFis on AAU in axSpA are from observational, open-label studies without parallel comparator arms. However, there is a growing body of evidence describing the impact of the TNFi certolizumab pegol (CZP) on the incidence of axSpA-associated AAU.
    Objective: Our objective was to collate data pertaining to the impact of CZP in axSpA-associated AAU in patients across the full axSpA spectrum.
    Methods: Data were obtained from four industry-supported phase 3 and 4 clinical trials (C-VIEW, C-axSpAnd, C-OPTIMISE, and RAPID-axSpA). To supplement these data, a targeted literature review was performed through searches of MEDLINE, Embase, and reference lists.
    Results: Available data from 1467 patients from the C-VIEW, C-axSpAnd, C-OPTIMISE, and RAPID-axSpA trials show CZP to be effective in AAU in patients across the full axSpA spectrum, reducing AAU flares when compared with placebo or pretreatment period. No differences in AAU outcomes were reported when stratified by axSpA subgroup age or sex. The targeted literature review identified six further studies of CZP in spondyloarthritis-associated AAU, only one of which was specific to axSpA.
    Conclusion: CZP was effective in reducing AAU incidence in clinical trials with patients with axSpA. The targeted literature review, however, highlighted that there remains a paucity of data beyond these trials. Data from comparative studies would further enhance the body of evidence on the effects of CZP in patients with axSpA who develop AAU.
    Language English
    Publishing date 2022-09-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2783278-8
    ISSN 2198-6584 ; 2198-6576
    ISSN (online) 2198-6584
    ISSN 2198-6576
    DOI 10.1007/s40744-022-00486-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review.

    Baraliakos, Xenofon / Gensler, Lianne S / D'Angelo, Salvatore / Iannone, Florenzo / Favalli, Ennio G / de Peyrecave, Natasha / Auteri, Simone E / Caporali, Roberto

    Therapeutic advances in musculoskeletal disease

    2020  Volume 12, Page(s) 1759720X20906040

    Abstract: We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), in patients with ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis ( ...

    Abstract We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), in patients with ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis (nr-axSpA) treated with biologic therapy. Searches were limited to English language manuscripts published in the 11 years prior to 9 July 2019. Randomized controlled trials, open-label extensions (OLEs) and observational studies reporting mSASSS progression in patients with AS or nr-axSpA treated with biologics were eligible for inclusion. Bias was assessed using the methodological index for nonrandomized studies (MINORS) tool. Among the 322 studies identified in the literature search, 23 (11 OLEs and 12 cohort studies) met the eligibility criteria and were selected for inclusion. Most studies reported mSASSS progression in patients with AS receiving tumor necrosis factor inhibitor (TNFi) treatment. One study reported mSASSS progression in patients with AS treated with secukinumab, an interleukin-17A inhibitor. The mean (range) MINORS score was 11.3 (7-15) for the 15 noncomparative studies and 15 (12-22) for the 8 comparative studies. Although results of the individual studies were variable, mSASSS progression in patients with AS was generally minimal and slow with long-term TNFi therapy. Moreover, odds ratios for the likelihood of mSASSS progression with/without TNFi favoured TNFi therapy in several of the cohort studies. The rate of mSASSS progression following continuous secukinumab treatment was low and remained stable over 4 years. Of two studies reporting progression in patients with nr-axSpA treated with TNFis, one showed no mSASSS progression; however, the lack of control limited comparative conclusions.
    Language English
    Publishing date 2020-03-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2516075-8
    ISSN 1759-7218 ; 1759-720X
    ISSN (online) 1759-7218
    ISSN 1759-720X
    DOI 10.1177/1759720X20906040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: How advances in personalized medicine will change rheumatology.

    Selmi, Carlo / Kon, Elizaveta / De Santis, Maria / Favalli, Ennio G / Cimaz, Rolando / Generali, Elena / Sinigaglia, Luigi

    Personalized medicine

    2018  Volume 15, Issue 2, Page(s) 75–78

    MeSH term(s) Arthritis/diagnosis ; Arthritis/genetics ; Humans ; Precision Medicine/trends ; Rheumatology/methods ; Rheumatology/trends
    Language English
    Publishing date 2018-02-02
    Publishing country England
    Document type Editorial
    ZDB-ID 2299146-3
    ISSN 1744-828X ; 1741-0541
    ISSN (online) 1744-828X
    ISSN 1741-0541
    DOI 10.2217/pme-2017-0079
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top